bf/NASDAQ:ALZN_icon.jpeg

NASDAQ:ALZN

Alzamend Neuro, Inc.

  • Stock

0.67

+0.77%

−1.77

USD last updated 13/08 01:59:42

Last Close

2.44

12/08 20:00

Market Cap

3.52M

Beta: -

Volume Today

118.56K

Avg: 184.60K

PE Ratio

−0.38

PFCF: −0.69

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -10-52019-01-302020-01-302021-01-312022-09-132024-03-21

    Revenue (Estimate*)

    0.000.000.010.010.012019-01-302020-01-302021-01-312022-09-132024-03-21

    *Estimate based on analyst consensus